drugset / Trial / NCT04971200

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

NCT04971200

Phase 0 Completed 12 enrolled Premier Specialists, Australia
NaSingle-groupOpen-labelTreatment

Summary

Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world population. The purpose of this pilot study is to evaluate the effect and the safety of Tildrakizumab in adult participants with vitiligo.

Timeline

Start
2021-09-16
Primary completion
2024-11-10
Completion
2024-11-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tildrakizumab Monoclonal antibody 200 mg Subcutaneous